Advanced search
Publication Cover
Leukemia & Lymphoma Volume 54, 2013 - Issue 3
Submit an article Journal homepage
1,555
Views
10
CrossRef citations to date
0
Altmetric
Research Article

Lenalidomide (Revlimid), bortezomib (Velcade) and dexamethasone for heavily pretreated relapsed or refractory multiple myeloma

Victor H. Jimenez-ZepedaPrincess Margaret Hospital, Department of Medical Oncology and Hematology, Toronto, ON, Canada
,
Donna E. ReecePrincess Margaret Hospital, Department of Medical Oncology and Hematology, Toronto, ON, Canada
,
Suzanne TrudelPrincess Margaret Hospital, Department of Medical Oncology and Hematology, Toronto, ON, Canada
,
Christine ChenPrincess Margaret Hospital, Department of Medical Oncology and Hematology, Toronto, ON, Canada
,
Rodger TiedemannPrincess Margaret Hospital, Department of Medical Oncology and Hematology, Toronto, ON, Canada
&
Vishal KukretiPrincess Margaret Hospital, Department of Medical Oncology and Hematology, Toronto, ON, CanadaCorrespondence[email protected]
Pages 555-560 | Received 14 Mar 2012, Accepted 05 Aug 2012, Published online: 02 Jan 2013

Citations (10)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

Yinyin Xu, Bingda Chen, Suraj K George & Beizhong Liu. (2015) Downregulation of MicroRNA-152 contributes to high expression of DKK1 in multiple myeloma. RNA Biology 12:12, pages 1314-1322.
Read now

Articles from other publishers (9)

Xavier Leleu, Francesca Gay, Anne Flament, Kim Allcott & Michel Delforge. (2017) Incidence of neutropenia and use of granulocyte colony-stimulating factors in multiple myeloma: is current clinical practice adequate?. Annals of Hematology 97:3, pages 387-400.
Crossref
Zhiwei Ji, Jing Su, Dan Wu, Huiming Peng, Weiling Zhao, Brian Nlong Zhao & Xiaobo Zhou. (2016) Predicting the impact of combined therapies on myeloma cell growth using a hybrid multi-scale agent-based model. Oncotarget 8:5, pages 7647-7665.
Crossref
Alexandra P. PunkeJ. Aubrey Waddell & Dominic A. SolimandoJrJr. (2017) Lenalidomide, Bortezomib, and Dexamethasone (RVD) Regimen for Multiple Myeloma. Hospital Pharmacy 52:1, pages 27-32.
Crossref
Inger S. NijhofLaurens E. FranssenMark-David LevinGerard M. J. BosAnnemiek BroijlSaskia K. KleinHarry R. KoeneAndries C. BloemAart BeekerLaura M. FaberEllen van der SpekPaula F. Ypma, Reinier RaymakersDick-Johan van Spronsen, Peter E. WesterweelRimke OostvogelsJeroen van VelzenBerris van KesselTuna MutisPieter SonneveldSonja ZweegmanHenk M. LokhorstNiels W. C. J. van de Donk. (2016) Phase 1/2 study of lenalidomide combined with low-dose cyclophosphamide and prednisone in lenalidomide-refractory multiple myeloma. Blood 128:19, pages 2297-2306.
Crossref
J J Shah, L Feng, S K Thomas, Z Berkova, D M Weber, M Wang, M H Qazilbash, R E Champlin, T R Mendoza, C Cleeland & R Z Orlowski. (2016) Siltuximab (CNTO 328) with lenalidomide, bortezomib and dexamethasone in newly-diagnosed, previously untreated multiple myeloma: an open-label phase I trial. Blood Cancer Journal 6:2, pages e396-e396.
Crossref
Hye Ji ChoiTae-Hee KimSoo Ah KimJun-Mo KimArum LeeHyeon Jin SongYoo Jin Park. (2016) Cell Therapy Products in Menopausal Medicine. Journal of Menopausal Medicine 22:2, pages 71.
Crossref
Jatin J. ShahEdward A. StadtmauerRafat AbonourAdam D. CohenWilliam I. BensingerCristina GasparettoJonathan L. KaufmanSuzanne LentzschDan T. VoglChristina L. GomesNatalia PascucciDavid D. Smith, Robert Z. OrlowskiBrian G. M. Durie. (2015) Carfilzomib, pomalidomide, and dexamethasone for relapsed or refractory myeloma. Blood 126:20, pages 2284-2290.
Crossref
Paul G. RichardsonWanling XieSundar JagannathAndrzej JakubowiakSagar LonialNoopur S. RajeMelissa AlsinaIrene M. GhobrialRobert L. SchlossmanNikhil C. MunshiAmitabha MazumderDavid H. VesoleJonathan L. KaufmanKathleen ColsonMary McKenneyLaura E. LundeJohn FeatherMichelle E. MaglioDiane WarrenDixil FrancisTeru HideshimaRobert Knight, Dixie-Lee Esseltine, Constantine S. MitsiadesEdie WellerKenneth C. Anderson. (2014) A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myeloma. Blood 123:10, pages 1461-1469.
Crossref
Maria T. Petrucci, Pilar Giraldo, Paolo Corradini, Adriana Teixeira, Meletios A. Dimopoulos, Igor W. Blau, Johannes Drach, Ralf Angermund, Nathalie Allietta, Esther Broer, Vivien Mitchell & Joan Bladé. (2013) A prospective, international phase 2 study of bortezomib retreatment in patients with relapsed multiple myeloma. British Journal of Haematology 160:5, pages 649-659.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.